PurposeOral fluoropyrimidine (S-1. capecitabine) has been considered as an important part of various regimens. We aimed to evaluate the efficacy and safety of S-1-based therapy versus capecitabine -based therapy in gastrointestinal cancers. MethodsEligible studies were identified from Pubmed. https://cascadianaturales.shop/product-category/donation/